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”Där bor små fina älvor bak mossig jättesten. 
De kommer fram och dansar ibland i månens sken, 
Och tomtebarnen tycker, att inte någonting 
kan vara lika vackert som älvorna i ring. 
 
Så lätt och späd är älvan, men tomten tung och tjock, 
Det märktes häromafton, de skulle gunga bock. 
Fast älvorna var åtta och barnen bara två 
Det ville inte lyckas att väga jämt ändå.” 
 
   From Tomtebobarnen by Elsa Beskow, 1910 
© Bonnier Carlsen  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Kalle and Jens 
& 
To the children with liver disease 
  
ABSTRACT 
About 100 new children in Sweden require care at a tertiary pediatric ward each year for severe 
liver disease. These children are at risk for both severe gastrointestinal bleeding, which may be 
life threatening, and intra- or extrahepatic thrombosis. Both pro- and anticoagulant factors are 
synthesized in the liver and their levels decrease as liver failure progresses. Coagulation factors 
are thus used as prognostic tests. The balance between pro- and anticoagulant mechanisms, 
although maintained in liver disease, seems to be instable and can easily tip towards either 
bleeding or thrombosis. The coagulation system in children undergoes age-specific changes and 
the etiology and/or pathogenesis of pediatric liver diseases is different than in adults.  
 
The aims of this thesis were to improve the treatment and the analysis of coagulation defects in 
pediatric liver disease and also to improve the prognostic evaluation in liver disease. 
In Study 1 children with liver disease were treated with recombinant FVIIa due to life 
threatening bleeding or as prophylaxis prior to invasive procedures. In the first group, the 
bleeding decreased in 50% of the evaluated occasions and a combination of rFVIIa and 
octreotide in gastrointestinal hemorrhage was advantageous. In the second group, rFVIIa was 
useful as prophylactic treatment before various diagnostic and therapeutic procedures.  
In Study 2 the thrombin generation test was evaluated in children with liver disease, with and 
without increased bleeding risk. The results were compared to age-matched healthy controls. 
This assay did not provide additional information compared to routine coagulation tests. 
In Study 3 the correlation between bile acids and coagulation factors was investigated. In 
children with markedly elevated levels of bile acids, i.e. above 200 µmol/L, the levels of 
coagulation factors increased with rising levels of bile acids, despite a worse clinical outcome. 
In an in vitro study, no interference between bile acids and coagulation factor concentrations 
was detected.  
In Study 4 the Owren method for analyzing INR in patients with liver disease was assessed. 
Plasma samples from adult patients with liver disease were analyzed at eight laboratories. The 
coefficient of variance between the laboratories was 5.3%, which is low. Additionally, the 
ISIVKA and ISIliver were determined and the difference between them was below 10%. These 
results show that the previously reported high interlaboratory variability regarding INR in 
patients with liver disease does not constitute a problem when Owren-based reagents are used. 
 
Conclusion: rFVIIa is beneficial for selected patients with severe bleeding and as prophylactic 
treatment. However, with current knowledge regarding coagulation in liver disease, new 
treatment strategies aiming to maintain the hemostatic balance in critical situations need to be 
studied. The thrombin generation test did not provide more information than routine tests. A 
modified method might be more successful. Coagulation factors may be questionable as 
prognostic markers in patients with highly elevated bile acids. The mechanisms behind the 
effect of high bile acids on the coagulation system are very important targets of further studies. 
Finally, Owren-based reagents for measurement of INR in patients with liver disease provide a 
solution to the problem with high interlaboratory variability seen internationally.  
 
This thesis adds important information regarding several aspects of the coagulation in children 
with liver disease and highlights directions for future research.  
Keywords: FVIIa, thrombin generation, cholestasis, bile acids, prognosis, INR, ISI, Owren  
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1 BACKGROUND 
 
The liver is the largest solid organ in the body and has several important functions 
including metabolism of nutrients, synthesis of proteins and detoxification. Bile, which 
is important for the absorption of fat and fat-soluble vitamins, is also produced in the 
liver [1].  
The micro-anatomy of the liver is shown in Figure 1. The liver consists predominantly 
of cords of hepatocytes. The walls of adjacent hepatocytes form bile canaliculi which 
empty into intrahepatic bile ducts formed by cholangiocytes. Blood enters the liver via 
the portal vein and the hepatic artery and flows slowly through the sinusoids, which are 
lined by endothelial cells, to the central vein.  
 
 
 
 
Figure 1: The micro-anatomy of the liver from Martini, Frederic H.; Nath, Judil.; 
Bartholomew, Edwin F,. Fundamentals of anatomy & physiology, 9th Edition, © 
2012. Reprinted by kind permission of Pearson Education, Inc., Upper Saddle River, 
NJ  
 
In the fetus, liver structures develop from cells of different origins. The hepatocytes and 
the cholangiocytes are derived from the liver bud, which consists of endodermal 
epithelium of the foregut. The cells lining the sinusoids are derived from mesodermal 
mesenchymal cells. The extrahepatic bile ducts, which drain the intrahepatic bile ducts, 
are formed from the intestine [1, 2].  
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1.1 PEDIATRIC LIVER DISEASE 
 
Hepatic health problems are uncommon in children. Still, about 100 new pediatric 
cases in Sweden require care at a tertiary pediatric ward each year due to liver disease. 
There are numerous different liver diseases that may affect neonates, infants and 
children. The etiologic and pathogenic spectrum varies to a great extent with age at 
presentation [3]. Many of the diseases have a genetic component; these diseases may be 
subclassified as chromosomal, single gene (Mendelian) and complex. The complex 
diseases are multifactorial and caused by interplay between several genes and the 
environment. The clinical picture, thus, differs between patients [4].  
According to etiology and/or pathogenesis, pediatric liver disease can be subdivided as 
follows. Selected examples are given for each group.  
 
Abnormal development: Micro- and macroanatomical anomalies in the structure of 
the hepatobiliary system caused during the fetal or early neonatal period, for example: 
biliary atresia, Alagille’s syndrome, congenital liver fibrosis, choledochal cyst.  
 
Infections: Diseases caused by bacteria, viruses or parasites, for example: hepatitis B, 
hepatitis C, cytomegalovirus, Epstein-Barr virus, liver abscess. 
 
Inborn errors of metabolism: Defects in the synthesis, turnover, breakdown and 
elimination of amino acids, proteins, carbohydrates and lipids, causing acute or chronic 
intoxication by some intermediary product or leading to a defective or absent function. 
These patients may have hepatic and/or extrahepatic symptoms. Examples of metabolic 
diseases with hepatic presentation: tyrosinemia, Wilson’s disease, progressive familial 
intrahepatic cholestasis (PFIC), Aagenaes syndrome, glycogen storage disease, non-
alcoholic steatohepatitis (NASH). 
 
Immune-mediated disorders: Diseases caused by an inappropriately targeted reaction 
of the immune system, for example: autoimmune hepatitis, sclerosing cholangitis, 
neonatal systemic lupus erythematosus, graft versus host disease. 
 
Xenobiotic-induced liver injury: Liver damage caused by pharmaceutical, chemical, 
herbal or nutritional agents, for example: Reye’s syndrome, acetaminophen/ 
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paracetamol-induced damage, venoocclusive disease (VOD), total parenteral nutrition 
associated cholestasis. 
 
Vascular disorders: Symptoms caused by changes in blood flow in intra- and/or 
extrahepatic vessels or focal changes in the blood flow, for example portal vein 
thrombosis, portal vein stenosis, porto–systemic shunt, as well as sickle cell disease, 
and congestive heart failure. 
 
Neoplasms: Benign or malignant tumors (primary or metastases) for example: 
hepatoblastoma, hepatocellular carcinoma, adenoma. 
 
1.1.1 Cholestasis 
This condition implies an impaired canalicular flow of bile, owing either to reduced 
synthesis of bile or an obstruction in the biliary tree [5]. The immediate consequence of 
cholestasis is the intracellular accumulation of lipophilic substances in the hepatocytes. 
This will cause deranged or altered hepatocytic functions. Soon, the cholestasis will 
also lead to decreased intraluminal gut concentration of bile compounds including bile 
acids, causing fat malabsorption [6]. Newborn children are especially prone to develop 
cholestasis and this syndrome in a neonate is referred to as neonatal cholestasis. The 
most common causes of neonatal cholestasis are biliary atresia, α-1-antitrypsin 
deficiency and PFIC [7]. However, several of the different diagnoses listed above can 
cause this condition and in the final stage of their course most hepatic diseases show 
cholestatic features [8].  
 
1.1.2 Acute liver failure 
This clinical condition is defined by the following criteria: (1) no evidence of chronic 
liver disease (2) biochemical evidence of acute liver injury (3) hepatic-based 
coagulopathy that is not corrected by parenteral administration of vitamin K. In 
addition hepatic encephalopathy must be present if INR 1.5-1.9, but is not required if 
INR is equal to or greater than INR 2.0 [9]. The most common causes of acute liver 
failure in children are metabolic diseases, autoimmune disease and infectious diseases. 
Survival rates, without liver transplant, are reported to be 41-94%, depending on 
etiology [10].  
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1.1.3 End stage liver disease 
 
Chronic liver disease of various etiologies can progress into liver failure and end-stage 
liver disease. Cirrhosis is the common final pathway of all chronic liver diseases. It is 
caused by an abnormal regeneration which replaces injured hepatic tissue by high 
amounts of fibrous tissue. This progressive fibrosis disrupts the normal 
microcirculation of the liver and causes decreased hepatocellular function and portal 
hypertension [3, 11]. Hepatocellular insufficiency might lead to secondary failure of 
other organs such as the kidneys, lungs, the gastrointestinal tract and finally the central 
nervous system. 
 
1.1.4 Portal hypertension 
Portal hypertension is defined as a pathological increase in the pressure of the portal 
venous system [12]. Apart from cirrhosis, this can also be caused by extrahepatic portal 
vein obstruction including portal vein thrombosis. Portal hypertension can lead to the 
development of ascites, splenomegali and formation of oesophageal and rectal varices 
[13]. Rupture of these varices causes severe gastrointestinal bleeding, which may be 
life threatening [14].  
 
1.1.5 Routine methods for assessment of liver disease  
(Selected examples below are tests of importance in this thesis) 
 
Laboratory test: assays for the evaluation of: a) synthetic function (albumin, INR), b) 
hepatocyte integrity (ALT, AST) and c) markers of cholestasis (GT, ALP, Bilirubin, 
total and conjugated, FSBA).  
Imaging techniques: Ultrasound, CT-scan, scintigraphy, elastography, MRI.  
Procedures: Liver biopsy, endoscopy. 
 
1.1.6 Treatment 
The therapeutic alternatives for liver diseases include nutritional support, 
pharmacological treatment, surgical procedures and in selected cases liver 
transplantation [3, 10, 13, 15-17]. 
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1.2 THE COAGULATION PROCESS 
After an injury to the wall of a blood vessel, the body responds in a three-step process: 
primary hemostasis, secondary hemostasis (Figure 2) and the tertiary hemostasis 
(Figure 3).  
 
1.2.1 Primary hemostasis 
Platelets in the circulation are slowed down at the site of the injury in the vessel wall, as 
a response to interaction with plasma proteins including von Willebrand factor (vWF) 
bound to subendothelial collagen. Subsequently, the platelets adhere to the 
subendothelial collagen and are activated. The activation includes; a conformational 
change important for the spread on subendothelial surfaces, release of granulae and 
exposure of receptors on the platelet surface. This promotes formation of platelet 
aggregates preventing further blood loss, and is important for the cell-based coagulation 
cascade (see below) [18, 19]. The primary hemostasis, thus, results in the formation of 
a platelet plug. 
 
1.2.2 Secondary hemostasis: The cell based model 
(Figure 2) 
The initiation phase: When an injury occurs at the vessel wall, activated Factor VII 
(FVIIa) binds to exposed tissue factor (TF). This complex activates Factor X (FX), 
which together with activated Factor V (FVa) activates a small amount of thrombin 
(FII). Though small, the quantity of thrombin formed during this phase starts the 
amplification phase.  
 
The amplification phase: The thrombin formed leads to further activation of the 
platelets that adhere to the collagen at the site of the injury. In addition, thrombin 
activates FXI to FXIa and the cofactor FV to FVa and uncouples the cofactor FVIII 
from its carrier protein vWF.  
 
The propagation phase: Complexes of FIXa – FVIIIa and FXa – FVa are formed on 
the activated platelet and a large amount of thrombin is generated that can cleave 
fibrinogen to form a fibrin network, a clot, which is stabilized by FXIII, antiplasmin 
and thrombin-activatable fibrinolysis inhibitor (TAFI) [20, 21].  
The secondary hemostasis thus results in stabilization of the platelet plug.  
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Figure 2: Overview of the cell based model, reproduced with kind permission from M. 
Hoffman, previously published in Journal of Thrombosis and Haemostasis 
2012;10:1478-1485.  
 
1.2.3 Anti-coagulant mechanisms 
The tissue factor pathway inhibitor (TFPI) inhibits the initiation phase of the 
coagulation system by binding and deactivating FXa associated to the TF-FVIIa 
complex, and then prevents further activation of FX [22]. Antithrombin inhibits the 
function of thrombin, FIXa, FXa and FXIa. The anticoagulant effect of antithrombin is, 
however, dependent on binding to heparin sulfate on the endothelium, and thus 
localized to the vessel wall [23]. Thrombin is also inactivated by α2-macroglobulin and 
heparin cofactor II [24]. The protein C system inactivates the cofactors FV and FVIII. 
Protein C is activated by thrombomodulin (TM) at the endothelial cell surface. The 
activated protein C (APC) that is formed floats into the circulation. APC forms a 
complex with its cofactor Protein S to inhibit FV at a phospholipid surface. The 
inhibitory effect on FVIII also requires FV, as an additional cofactor [25].  
  
1.2.4 Tertiary hemostasis: The fibrinolytic system  
(Figure 3) 
Plasminogen is predominantly activated by tissue-plasminogen activator (t-PA) in the 
circulatory system. Both plasminogen and t-PA have a high affinity to fibrin. Thus, the 
active form of plasminogen, plasmin, is localized to the surface of the fibrin clot. The 
plasmin degrades the clot and when this process is completed the free plasmin is 
inactivated by antiplasmin. FXIII cross-links a small amount of antiplasmin to fibrin 
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which prevents early degradation of the clot. Plasminogen activator inhibitor-1 (PAI-1) 
regulates the activation of plasminogen by binding to t-PA [26].  
 
 
 
Figure 3: Overview of the fibrinolytic system, reproduced with kind permission from 
B. Wiman, previously published in MFR informerar, 1987. 
 
 
1.3 COAGULATION ASSAYS  
Blood sampling and preparation: The blood samples are preferably obtained with a 
conventional straight needle with a light tourniquet. Collection of samples from a 
central venous line infers a risk of contamination with heparin. Coagulation samples are 
collected into citrate tubes with the current recommended concentration of citrate, 
0.105-0.109 mol/L (3.2%). Most coagulation assays are performed on platelet-poor 
plasma (PPP). To prepare PPP, single or double centrifugation steps are required within 
30 minutes. PPP is divided into aliquots and snap frozen at -70 to -80˚C until analysis. 
Platelet rich plasma is used in assays evaluating the effect from the platelets and needs 
to be analyzed, in general, within 2 hours [27-29].  
 
Platelet function tests: Various methods are used for evaluation of platelet function 
for example, template bleeding time, platelet aggregometry, platelet function analyzer 
(PFA-100™), flow cytometry and Verify now [30]. 
 
Routine coagulation assays: Automated assays are available for prothrombin time 
/INR, APTT, fibrinogen, antithrombin and D-dimer, with results provided by the 
hospital laboratory within 2 hours.  
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Specific coagulation assays: Generally, the pro-coagulant factors: FII, FV, FVII, 
FVIII, FIX, FX, FXI, FXII, vWF and the anticoagulant proteins: protein C and protein 
S are analyzed at special coagulation laboratories.  
 
Global coagulation assays: There are several new global tests evaluating the thrombin 
generation or the clot formation and aimed to provide an overall assessment of the 
hemostatic capacity, for example, thrombin generation (TGT), thrombelastography, 
aPTT waveform analysis, Clot formation and Lysis assay and Overall Hemostatic 
Potential [31, 32].  
 
Selected examples below are tests of importance in this thesis 
 
1.3.1 Template bleeding time 
This method is used for the evaluation of the platelet function. A standardized incision 
is made with a disposable template device and the time for the blood flow to cessation 
is measured. Except for platelet function, the result is dependent on platelet count, level 
of vWF and vascular pattern. This test has a low reproducibility and is highly 
dependent on operator technique [33].  
 
1.3.2 Prothrombin time/INR 
This test is widely used to monitor treatment with vitamin K antagonists. There are two 
different methods to measure the prothrombin time (PT): the Quick method and the 
Owren method. The result of the Quick method is dependent on the levels of FII, FVII, 
FX, which are vitamin K dependent, and on FV and fibrinogen [34]. The Owren 
method is only dependent on the levels of FII, FVII and FX since depleted bovine 
plasma containing FV and fibrinogen is added to the sample prior to the analysis [35]. 
The result of the PT-assay can be reported in seconds or as percent of the PT activity in 
normal plasma (PT %). However, several different reagents and instruments are in use 
for measurement of PT, causing differences in results from different laboratories. To 
reduce these differences, the INR system was developed for reporting of PT results. 
Within this calibration system a correction factor, the international sensitivity index 
(ISI) is used. The ISI is obtained from a procedure where plasma from patients treated 
with vitamin K antagonists and from normal controls is analyzed with a reference 
reagent from WHO and with the reagent in use at the specific laboratory. The ISI and 
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the measured prothrombin time with the local reagent can then be used in the formula: 
INR = (patient PT / mean normal PT)
ISI
 to obtain the results in INR [36].  
 
1.3.3 Activated partial thromboplastin time (APTT)  
This is a screening test to detect reduced levels of FXI, FIX, FVIII, FX, FV, FII and 
fibrinogen. The test is activated by contact activation and reduced levels of FXII can 
also lead to a prolonged APTT. However, FXII deficiency is not associated with an 
increased bleeding tendency. Other causes of prolonged APTT, without bleeding 
symptoms, are low levels of high molecular weight kininogen and prekallikrein or 
circulating lupus anticoagulants and/or antiphospholipid antibodies [27].  
 
1.3.4 The thrombin generation test 
The first thrombin generation method was developed by McFarlane et al. in 1953 [37]. 
However, the method was considered too complicated and time-consuming to be a part 
of clinical coagulation testing. However, after several modifications by Hemker et al., it 
is now increasingly being used [38-40]. This test measures the continuous generation of 
thrombin in plasma. The parameters obtained from the analysis are, endogenous 
thrombin potential (ETP), peak height, Lag time (LT), and time to peak (TTP) (Figure 
4). ETP is the area under the curve which reflects the amount of thrombin generated 
and is given in nanomolar thrombin per minute. Peak height corresponds to the 
maximum of thrombin generation and is reported in nanomolar thrombin. Lag time is 
the time in minutes until the thrombin generation starts. TTP is the time in minutes until 
the peak occurs [41].  
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Figure 4: The different parameters of the thrombin generation in two patients with 
liver disease. 
 
There are different TGT methods. The fluorogenic Calibrated Automated 
Thrombogram (CAT) method according to Hemker (Thrombinoscope BV, Maastricht, 
The Netherlands) has been used in most publications concerning thrombin generation. 
With this method, as each sample is run, calibration curves are created simultaneously 
using a thrombin calibrator, in order to correct for the activity of the α2-macroglobulin 
complex, inner filter effect and substrate consumption. Both platelet-poor plasma and 
platelet-rich plasma can be used for this assay as well as reagents of different tissue 
factor concentrations [42, 43]. Efforts are being made to deal with standardization 
issues regarding this method [28, 41, 44].  
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1.4 COAGULATION IN CHILDREN: DEVELOPMENTAL HEMOSTASIS 
The coagulation system in children undergoes age-specific changes and differs from 
that in adults. During infancy and childhood the coagulation system seems to function 
well, providing a reduced risk of thrombosis without an increased risk of bleeding [45, 
46]. The incidence of thrombotic events, however, is increasing due to better survival 
of children with severe diseases, to the use of central venous lines and to improved 
imaging techniques [47]. The risk of thrombosis is highest in the neonatal period and in 
adolescents. Studies in clinically stable children who had undergone a liver 
transplantation, receiving a liver from an adult donor, show that the liver graft produces 
coagulation factors and inhibitors according to the pediatric profile. Thus the liver itself 
does not regulate the plasma levels of hemostatic proteins [48]. Age-specific reference 
ranges for different coagulation assays in healthy children have mainly been provided 
by three groups: Andrew et al., Monagle et al. and recently Appel et al. [46, 49-51]. 
There are a few more studies that provide reference ranges in fetuses and neonates 
[24]. The reference ranges are specific for each combination of instrument and reagent 
[24, 51].  
 
1.4.1 Primary and secondary hemostasis 
 
Platelets: The platelet counts in children are similar to those in adults. Neonatal 
platelets are hyporesponsive compared to adult platelets. For example, they have lower 
expression of adhesion receptors and a weaker response to thrombin [52].  
vWF and FVIII: The levels of vWF are high from birth until 6 months of age. The 
lowest levels are documented at one year of age after which they rise to adult levels. A 
reduced cleavage of vWF in infants, due to lower levels of ADAMTS-13, might 
explain the higher levels this age-group [51, 53]. The levels of FVIII were elevated in 
the neonatal period in one study [46]. In another study the mean FVIII value in the 
neonates was the same as in adults. However, a skewed distribution towards very high 
levels was noted [49]. In both these studies, the levels subsequently decreased and a 
nadir was reached between 1 month and 1 year of life, before increasing to adult levels 
[46, 49, 50]. A third study showed instead a gradual increase the entire childhood. 
However, the youngest children enrolled in the study were between 1-6 months of age 
[51].  
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Vitamin K dependent coagulation factors and FV: The studies demonstrate low 
levels of vitamin K dependent coagulation factor in the neonatal period [46, 49]. 
Although levels increase during childhood, adult levels are not reached until the age of 
16 years. The changes in the concentration of FV during childhood show a somewhat 
different pattern, with levels in the age group 11-16 years, decreasing to the low levels 
seen in the newborns [46, 49, 51].  
 
Fibrinogen: Fibrinogen is elevated in the neonatal period, decreases in children aged 1 
month to 1 year, and subsequently increases with age [46]. The age at which adult 
levels are reached differs between the studies and is reported as 1 year, 6-10 years and 
18 years, respectively [46, 50, 51]. 
 
Specific anticoagulant proteins: Proteins S and C are low in the neonatal period and 
increase during the first year. The levels of protein C nevertheless remain lower than 
adult levels until 16 years of age in all three studies [46, 50, 51]. The published results 
on the levels of protein S between the ages of 1 and 16 years are contradictory, being 
reported as significantly elevated [46], not significantly different [50] and significantly 
lower [51] compared to the levels in adults. The levels of antithrombin are low in 
neonates; however, from 1 month until 16 years of age the levels are increased by 10% 
compared to adults in two studies [45, 46]. However, the levels of antithrombin were 
low or equal to the levels of adults throughout childhood in the third study [51]. The 
low levels of antithrombin in the neonatal period might be of physiologic importance 
since antithrombin has anti-angiogenic properties. Conversely, another important 
inhibitor of thrombin, Α-2 macroglobulin, is present at high levels in neonates [24].  
 
INR: The Quick method has been used to obtain the reference ranges regarding INR in 
children. INR is elevated in the youngest children and might be slightly elevated 
throughout childhood [46].  
 
APTT: APTT is increased in the neonatal period, probably due to increased levels of 
the contact activators including FXII, FXI, high molecular weight protein and 
kininogen [24]. Transient antiphospholipid antibodies are also more common in 
children, which can prolong the test results [54]. 
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TGT: A few reports on reference ranges in children have been published, showing that 
ETP increases with age [46, 55, 56]. However, several different reagents and 
instruments are used, and these influence the results. The CAT method is the method 
that has come closest to standardization. This method was used in a study by Tripodi et 
al., who found that neonates have the same results on the TGT as adults if 
thrombomodulin was added to the tests for both groups [57]. The plasma levels of 
thrombomodulin are increased in the neonatal period [24].  
 
1.4.2 Tertiary hemostasis  
Neonates have a reduced fibrinolysis due to low levels of plasminogen and PAI-1. Low 
levels of t-PA are also seen [58].  
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1.5 COAGULATION IN LIVER DISEASE 
1.5.1 Bleeding symptoms  
Bleeding symptoms are common in children with chronic liver disease, especially from 
the mucosal membranes, including nosebleeds and gastrointestinal hemorrhage [13, 59-
61]. Life-threatening bleeding episodes may also occur in other sites, such as 
intracranially [62]. Varicose veins develop secondary to portal hypertension and about 
40% of children with biliary atresia, without liver transplant, have had bleeding from 
esophageal varices by the age of 5 years [13]. These bleeding episodes can be life-
threatening and a mortality of 50% within 4 months has been described in children with 
recurrent variceal bleeding in combination with biliary atresia if bilirubin was above 10 
mg/dL [59].  
The most important factor for the development of a bleeding from varicose veins is the 
increase in portal pressure [14]. There is also an association between bacterial 
infections and episodes of bleeding from varicose veins in patients with cirrhosis [63]. 
A heparin-like effect secondary to the infection has been suggested as the mechanism 
[64]. Randomized trials have shown that antibiotic prophylaxis prevents rebleeding [65, 
66]  
 
Patients with liver disease often undergo various invasive procedures, of which liver 
biopsy and central line placement are the most common in pediatric patients. In a recent 
evaluation of risk factors for bleeding with ultrasound-guided liver biopsy, a drop in 
hemoglobin count of more than 2.0 g/dL was recorded in 1.5% of the 275 biopsies 
performed [67]. In the study, prophylactic treatment was given to all patients with INR 
>1.7 and/or platelet count below 70×10
9
 cells/L in the form of platelet concentrates, 
prothrombin complex concentrates (PCC) and/or plasma. From other studies, major 
complication rates of 1-4.6% have been reported in pediatric patients undergoing liver 
biopsy [68-70]. Also in these studies, the patients were given pretreatment to correct of 
coagulopathies and platelet counts. Increased complication rates have been shown in 
infants, children with acute liver failure, focal lesion, malignancy, previous bone 
marrow transplantation, and those treated with low molecular weight heparin (LMWH) 
[67, 71-73].  
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1.5.2 Thrombotic symptoms 
The most common thrombotic events in children with liver disease are portal vein 
thromboses (PVT) which can cause portal hypertension and also complicate a liver 
transplantation. The prevalence of PVT in children undergoing liver transplantation is 
3.7-10% and the condition may be associated with a higher post-transplant mortality 
[74, 75]. The prevalence of PVT in cirrhotic adult patients without malignancy is 10-
20% [76]. A reduced portal flow velocity has been shown to be important for the 
development of PVT in patients with cirrhosis [77]. The incidence of venous 
thromboembolism in adult chronic liver disease is reported to be 0.5-6.3% as compared 
to 4-15% in hospitalized patients with medical disorders [78]. Corresponding studies 
regarding the incidence of VTE in children with liver disease are lacking.  
 
Several studies in both animal models and in patients with liver disease have shown an 
increased progression to cirrhosis in patients with hypercoagulability. This association 
has mostly been described in patients with chronic viral hepatitis and thrombotic risk 
factors including FV Leiden, reduced levels of protein C, antithrombin and fibrinogen 
and/or increased levels of FVIII or homocysteine [79]. Conversely, patients with 
hemophilia and chronic hepatitis C have a slower progression of liver fibrosis [80]. The 
most predominant theory behind this increased hepatic fibrinogenesis is the ”direct 
stellate activation”. This model focuses on thrombin- or FXa-mediated activation of 
hepatic stellate cells leading to secretion of extracellular matrix proteins and 
fibrogenesis. Increased thrombin generation in the circulation in patients with cirrhosis 
and hypercoagulopathy might enhance this activation [81]. The potential use of 
anticoagulant treatment to reduce fibrinogenesis has been investigated in several animal 
studies with encouraging results [79]. One study of 34 patients (age 14-70 years) with 
chronic hepatitis B who were treated with heparin/LMWH for 3 weeks showed a 
treatment-related reduction in collagen fibrils in liver biopsies [82]. A study evaluating 
use of vitamin K antagonists to prevent fibrosis in patients with hepatitis C is ongoing 
[83]. 
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Veno-occlusive disease (VOD): This severe condition is also called sinusoidal 
obstructive syndrome or SOS. It is a xenobiotic-induced liver injury predominantly 
occurring after hematopoietic stem-cell transplantation. The condition is more common 
in children than adults and causes jaundice, painful hepatomegaly, ascites, weight gain 
within 30 days after transplantation [84]. The pathogenesis includes a toxic effect by 
chemotherapy on the sinusoids of the liver, causing swelling and hypoxia. Disruption of 
the sinusoidal endothelial lining leads to accumulation of cell debris in the venous 
veins. Furthermore, fibrin deposition within sinusoids and veins causes 
microthrombosis and fibrosis. Subsequently, the congestion of the liver causes portal 
hypertension [85]. In patients who develop a secondary multi-organ failure, mortality is 
more than 85% [86]. An upregulation of thrombomodulin, TFPI, PAI-1 P-selectin and 
soluble tissue factor is documented in VOD. The association with hereditary 
prothrombotic factors it not clarified, but prothrombin gene 20210G-A-mutation and 
Factor V Leiden may be associated [85].  
 
 
1.5.3 Coagulation mechanisms associated with bleeding  
 
Primary hemostasis:  
 
Reduced platelet count/platelet dysfunction: Thrombocytopenia (platelet count 
below 150 x10
9/
L occurs frequently in liver disease [18, 87]. The most common 
explanation has been a sequestration of platelets in the spleen secondary to portal 
hypertension [88]. However, there is no correlation between platelet count, portal 
pressure and the spleen size. Kinetic studies using radiolabelled platelets in kinetic 
studies show that platelets seem to be destroyed in the spleen instead of just being 
pooled [87]. Increased destruction of platelets has also been attributed to platelet 
associated antibodies, especially in hepatitis C, and to endotoxemia with or without 
disseminated intravascular coagulation [18]. Other causes of thrombocytopenia are 
decreased platelet production due to bone marrow suppression and changed metabolism 
of the platelet growth factor thrombopoietin (TPO) which is synthesized in the liver 
[18]. Reduced levels of TPO have been shown in children with cirrhosis and 
thrombocytopenia [89]. However, in general, the results from different studies 
concerning TPO in liver disease are contradictory and the laboratory assays are not 
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standardized. A large trial to evaluate use of a TPO-receptor agonist (eltrombopag) 
before procedures in cirrhotic patients with thrombocytopenia showed a reduced need 
for platelet transfusions but had to be closed due to an increased incidence of portal 
vein thrombosis [90]. Platelet dysfunction is common in liver cirrhosis according to 
platelet aggregation tests and template bleeding time [91, 92]. Both these tests are 
influenced by the number of platelets.  
 
Secondary hemostasis:  
 
Reduced levels of specific coagulation factors: Most of the coagulation factors are 
produced in the liver and the levels of FII, FV, FVII, FIX, FX and FXI fall as 
parenchymal cell damage increases [93]. In patients with concomitant vitamin K 
deficiency a further reduction of the vitamin K dependent factors (FII, FVII, FIX and 
FX) is seen secondary to impaired γ-carboxylation, especially in cholestatic liver 
disease [94].  
 
Decrease in fibrinogen: Fibrinogen is also synthesized in the liver and the levels are 
often reduced in patients with moderate to severe liver disease [93]. Dysfunctional 
forms of fibrinogen have been described in liver disease [95]. 
 
Elevated INR: Prothrombin time is reported according to INR and is traditionally used 
to evaluate of the risk of bleeding as well as for prognostic purposes in liver disease. 
PT/INR is also widely used to monitor VKA treatment and the INR system to report the 
prothrombin time was developed specifically for this group of patient. Several studies 
have shown that when the Quick method is used on plasma from patients with liver 
disease, the results in INR are highly variable [96-99]. To overcome this problem an 
alternative calibration has been proposed where plasma from patients with liver disease 
is used to obtain an ISI specific for this patient group, ISIliver [100, 101]. However, this 
system has never been taken to clinical practice [102].  
 
APTT: This test can be normal or prolonged in liver disease. A prolongation may 
reflect reduced plasma levels of coagulation factors or circulating antiphospholipid 
antibodies or lupus anticoagulants [103]. 
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Tertiary hemostasis: 
 
Hyperfibrinolysis: Thrombin-activatable fibrinolysis inhibitor (TAFI), alpha2-
antiplasmin and FXIII are synthesized in the liver and their levels are reduced in liver 
cirrhosis. Tissue-plasminogen activator (t-PA) is often elevated due to decreased 
clearance in the liver [104].  
 
1.5.4 Coagulation mechanisms associated with thrombosis 
 
Primary and secondary hemostasis: 
 
Platelet dysfunction: Recent data from flow cytometry, platelet-monocyte aggregate 
analysis and measurement of soluble P-selectin is consistent with hyperactivation of 
platelets [18]. In a mouse model, P-selectin mediated platelet aggregation in liver 
sinusoids was shown to contribute to a large extent to development of liver injury in 
cholestasis [105].  
 
Increased levels of specific coagulation factors: The levels of von Willebrand factor 
(vWF) and FVIII are often elevated in liver disease [93]. vWF is synthesized by 
endothelial cells and megakaryocytes. It is stored in endothelial cells and platelets and 
circulates in plasma with FVIII as a carrier protein [106]. Both vWF and FVIII are 
acute-inflammatory proteins [107]. Increased levels of vWF in liver cirrhosis have been 
linked to endothelial perturbation induced by endotoxemia and to an increased vWF 
expression in the vasculature of portal areas and sinusoidal endothelial cells in the liver 
[108, 109]. Reduced clearance of vWF secondary to decreased activity of the cleavage 
protease ADAMTS-13, has also been discussed as a possible cause [110, 111]. vWF 
was recently shown to correlate with the portal pressure [112]. The very high vWF 
levels in liver disease may compensate for both a reduced function of the vWF 
molecule as well as for thrombocytopenia and platelet function defects in the primary 
hemostasis [111]. FVIII is expressed in sinusoidal endothelial cells in the liver, and also 
in kidney, spleen and lungs. The elevated levels of FVIII in liver disease seem to be 
related to prolonged half –life secondary to the increased levels of vWF and reduced 
clearance in the liver [109]. Further, increased release of FVIII from storage sites and 
enhanced secretion of FVIII from FVIII-producing cells might contribute to the 
elevated levels [110].  
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Increased levels of fibrinogen: Fibrinogen is an acute-phase protein elevated in 
inflammatory conditions and can thus be increased in patients with liver disease in an 
inflammation state [113, 114]. A study in human hepatoma cells has demostrated that 
activation of the FXR receptor can induce fibrinogen expression. Since bile acids are 
known to activate these receptors this could suggest a link between bile acids and 
fibrinogen synthesis [115].  
 
Reduced levels of specific anticoagulant proteins: The levels of antithrombin, protein 
S and protein C are reduced in liver disease as a result of diminished hepatocellular 
synthesis. Protein S and protein C are also vitamin K dependent and require vitamin K 
to undergo γ-carboxylation, necessary for proper physiologic function [107].  
 
Tertiary hemostasis: 
 
Hypofibrinolysis: The level of plasminogen is low in liver disease due to reduced 
synthesis in the liver. Plasminogen activator inhibitor 1 (PAI-1) acts as an acute-phase 
protein and can be elevated in acute liver failure [116, 117].  
 
1.5.5 Global assays in liver disease 
 
Thrombin generation test (TGT): Tripodi et al. evaluated thrombin generation with 
the CAT method in adult patients with cirrhosis and showed that the ETP was lower in 
cirrhotic patients than in controls. However, when thrombomodulin, which activates the 
protein C system, was added to the assay (TGT-thrombomodulin) there was no 
significant difference between the groups. This study was performed on platelet –free 
plasma with a tissue factor concentration of 1 pmol/L [118]. Adult patients with acute 
liver failure (ALF) have been evaluated with a similar protocol with corresponding 
results [117]. Further, another study enrolling patients with AFL showed higher ETP 
with TGT-thrombomodulin, than in controls, indicating a hypercoagulable state [119]. 
When platelet-rich plasma from patients with cirrhosis was analyzed with a TGT-
thrombomodulin assay, ETP correlated with the platelet count in the patients and the 
ETP in the patients was lower than in the controls. The platelet count is thus important 
for the result of the TGT in these patients [120]. Neither treatment with fresh frozen 
plasma (FFP) corresponding to 10 ml/kg nor transfusion of a standard dose of platelets 
in patients with liver disease affect the TGT result [121]. In summary, the results of the 
TGT in acute or chronic liver disease are highly dependent on whether 
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thrombomodulin is added to the test and if platelet-rich or platelet-poor plasma has 
been used.  
 
 
Thrombelastography: In this assay, the level of fibrinogen and the platelet count are 
strongly associated with the measured clot strength [122, 123]. The assay is fast and it 
is used together with standardized protocols to guide the clinician in the use of 
coagulation factor concentrates, transfusions and antifibrinolytic theraphy during liver 
transplantations [124, 125]. In a study, enrolling patients with acute liver failure 
heterogeneous results of the assay were obtained [119]. Hypercoagulability has been 
detected by thromboelastography in adult patients with primary biliary cirrhosis and 
primary sclerosing cholangitis [126].  
  
   21 
 
 
1.5.6 The concept of a balanced coagulation system 
The coagulation defects in liver disease, can thus affect both pro- and anticoagulant 
mechanisms. Historically, most focus was directed to prolonged prothrombin time 
/reduction in INR and the bleeding risk. During the recent years, however, evidence has 
been evolving supporting that the balance between pro- and anticoagulant mechanisms 
is maintained in liver disease, even though the levels differ from those seen in healthy 
individuals [127, 128]. As early as 1981, Ewe et al. reported that the duration of the 
bleeding after liver biopsies did not correlate with the prothrombin time, the platelet 
count or whole blood clot time. In the study, 200 adult patients with various liver 
diseases, including 21 cirrhotic patients, were enrolled. The liver biopsies were 
performed in the context of a laparoscopic procedure during which postoperative 
bleeding could be inspected visually [129]. De Boer et al. reported in 2005 that several 
transplant centers performed up to 30% of the liver transplantations without any blood 
transfusions [130]. This was supported by the thrombin generation tests performed by 
Tripodi et al. the same year, showing normal thrombin generation in patients with 
cirrhosis after addition of thrombomodulin [118]. However, the balance between the 
pro- and anticoagulant systems seems to be instable and can easily tip towards either 
bleeding or thrombosis [131]. 
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1.6 COAGULATION FACTORS AS PROGNOSTIC MARKERS  
 
Coagulation tests: Coagulation analyses are used as liver function tests and prognostic 
markers, since the levels of the coagulation factors, in general, decrease as the synthetic 
function of the liver deteriorates. FV is used in France as a prognostic marker in liver 
disease [132]. FV has a relatively long half-life, around 12 hours, to compare with FVII 
which has a half-life of only 5-6 hours [133]. Thus FVII has an advantage as a 
prognostic marker in acute liver failure [134]. The level of FVII has a large impact on 
the INR result and INR is the coagulation test most frequently used for prognostic 
purposes. INR is also included in the King’s College criteria for acute fulminant liver 
failure [135].  
 
Scoring systems: The most well established scoring systems for prognostic evaluation 
in liver disease are the Child-Turcotte-Pugh (CTP)-, MELD- and PELD scores which 
all include INR. The CTP was mainly intended for cirrhotic patients undergoing 
surgery but is also used for liver graft allocation before liver transplantation [136]. The 
CTP classification is based on INR, bilirubin, albumin and also the clinical parameters, 
degree of encephalopathy and ascites. The result is given as CTP class A, B or C of 
which class C reflects the most severe condition. The CTP score is not used in children.  
 
Since the evaluation of the clinical parameters in the score can diverge between 
different physicians a new scoring system, the model of end stage liver disease 
(MELD) was developed in 2000 [137]. This is used for patients with chronic liver 
disease, above 12 years of age and patients with MELD above 15 are prioritized for 
liver transplantation [138]. MELD is calculated according to:  
MELD Score = 10 × (0.957 x Log
e
(creatinine mg/dL) + 0. 378 × Log
e
(bilirubin 
mg/dL) + 1.120 × Log
e 
(INR) + 0.643).  
 
McDiarmid et al. developed the Pediatric end stage liver disease score (PELD) for 
children below 12 years of age [139]. PELD score is calculated as: 
PELD Score = 10 × (0.480 × Log e (bilirubin mg/dL)+1.857 × Log e (INR) -0.687 × 
Log e (albumin g/dL)+0.436 if <1 yrs+ 0.667 if growth failure (<2 SD) ).  
The average PELD score at time of liver transplantation was 11.5 for those patients 
where the PELD result was utilized to determine liver allocation, in the USA 2003-
2004 [140].  
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The difference in INR between different laboratories using the Quick method, has led 
to concomitant differences in MELD scores between different hospitals [96, 97]. The 
effect of interlaboratory variation in INR on the PELD score has not been evaluated.  
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1.7 PRODUCTS WITH EFFECT ON HEMOSTASIS 
 
Pro-hemostatic treatment used in liver disease 
 
1.7.1 Vitamin K1  
(Fytomenadion, Konakion Novum, Roche, Basel, Switzerland). Vitamin K is necessary 
for the γ-carboxylation of vitamin K dependent coagulation factors including FII, FVII, 
FIX and FX as well as the anti-coagulant factors Protein C and Protein S [141]. It is 
used to treat vitamin K deficiency and is given to newborns worldwide to prevent 
vitamin K deficiency bleeding (VKDB) [142]. Another indication is to reverse vitamin 
K antagonist treatment. The levels of the vitamin K dependent factors increase more 
rapidly after the treatment in children as than in adults and an effect on INR is often 
obtained within one hour in infants [142, 143]. Vitamin K can be administered orally, 
intramuscularly or intravenously. In patients whose vitamin K deficiency is associated 
with cholestasis or whose gut mucosa is affected, the intestinal absorption is reduced 
and intravenous or intramuscular treatment may be necessary [144].  
 
1.7.2 Desmopressin  
(Octostim, Ferring Pharmaceuticals, Saint-Prex, Switzerland) is a synthetic vasopressin 
analogue which selectively increases release of endogenous vWF from the 
endothelium. This leads to a secondary increase in FVIII levels [145]. Desmopressin 
can also improve the platelet adhesion by enhancing expression of glycoprotein1b on 
the platelet membrane [146]. The main indications are mild von Willebrand’s disease, 
mild hemophilia type A and platelet function defects. It is also used as prophylaxis 
prior to liver biopsy in patients with platelet defects, as indicated by a prolonged 
template bleeding time [147, 148]. Desmopressin was shown to be effective in cirrhotic 
patients undergoing dental extraction [149]. However, it has not been shown to be 
efficient in the treatment of bleeding from varicose veins [150]. Desmopressin activates 
the fibrinolytic system through an increase of t-PA and is often combined with 
tranexamic acid to reduce this effect [151]. Further, desmopressin, acting as antidiuretic 
hormone, may lead to hyponatremia and fluid retention, especially in young children, 
thus fluid overload needs to be prevented [152].  
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1.7.3 Tranexamic acid  
(Cyklokapron, Meda, Solna, Sweden) inhibits the fibrinolytic system by inhibiting the 
conversion of plasminogen to plasmin [153]. Tranexamic acid is used in 
hyperfibrinolytic conditions and in several different bleeding disorders including 
hemophilia, platelet defects and von Willebrands disease to prevent premature 
dissolution of the clot. Tranexamic acid reduces blood loss and the need for 
transfusion in elective surgery including major pediatric surgery [154, 155]. It has 
been used increasingly to counteract massive bleeding in recent years after the 
CRASH-2 study showed that it reduced mortality when used in adult trauma patients 
[156]. Randomized clinical trials are lacking concerning anti-fibrinolytic agents in 
upper gastrointestinal bleeding in patients with liver disease [157]. A Cochrane 
review on six randomized trial regarding tranexamic acid in liver transplantation 
states that no effect is seen from tranexamic acid on mortality, graft failure, blood loss 
or blood products used, compared to the control groups [158].  
 
1.7.4 Fibrinogen concentrate  
(Riastap, CSL Behring, Marburg, Germany) is derived from plasma and used to 
increase the fibrinogen levels in patients with congenital or acquired fibrinogen 
deficiency [159]. It is increasingly used in the surgical setting, including liver 
transplantation, to reduce the need for transfusion. Thromboelastography-guided 
administration is often used [160, 161]. The blood product cryoprecipitate, containing 
fibrinogen, is used in countries where this concentrate is unavailable  
 
1.7.5 Recombinant activated Factor VII (rFVIIa) 
 (NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark) is recombinant coagulation 
factor VII in its active form. It has a localized effect in the activation of FX on the 
platelet [20]. It is often referred to as a “bypassing agent” since it bypasses most of the 
coagulation cascade including the FVIIIa-FIXa complex and acts at the end of the 
cascade. rFVIIa reduces the INR level since it has a major impact on the INR assay. 
The best way to monitor the hemostatic effect of the treatment is still unknown [20, 
162]. rFVIIa has a shorter half-life in children than in adults [163]. rFVIIa was 
originally developed for patients with hemophilia and acquired inhibitors against 
exogenously administered FVIII or FIX [164]. Other indications are Factor VII 
deficiency and a severe form of platelet function disorder, Glanzman thrombastenia 
[165, 166] . It has, however, been tried in a variety of patient groups outside the 
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original indication (“off-label use”) to prevent or control active bleeding. The risk of 
arterial thromboembolic events is increased in elderly patients receiving rFVII on an 
“off-label” basis [167]. 
 
Prophylactic treatment with rFVIIa in liver disease (Table 1): Six studies have been 
published regarding prophylactic treatment with rFVIIa in patients undergoing hepatic 
procedures. The first was performed by Jeffers et al. in 2002 as rFVIIa was evaluated in 
laparoscopic liver biopsy in patients with cirrhosis and coagulopathy. The majority 
responded with a normalization of prothrombin time and 74% achieved hemostasis 
within 10 minutes after the biopsy [168]. Two placebo controlled randomized trials in 
patients undergoing partial hepatectomy did not show any effect on transfusion 
requirements [169, 170]. Further, three studies evaluated rFVIIa in liver transplantation 
[171-173]. Efficacy was shown in two of them i.e. a reduction in the number of patients 
receiving RBC transfusion and a reduction in blood loss, respectively [171, 173].  
 
Therapeutic trials with rFVIIa in liver disease (Table 1): Two double blind, placebo 
controlled trials have been performed in patients with cirrhosis and upper 
gastrointestinal hemorrhage [174, 175]. The results of the first study showed no overall 
benefit from rFVIIa; however, a subgroup analysis of patients with CTP class B or C it 
showed that the number of patients who failed to control bleeding was reduced in the 
group given rFVIIa [174]. Thus, a second study in patients with CTP class B or C was 
performed, but no difference was confirmed regarding the primary composite endpoint 
(failure to control 24-hour bleeding, or failure to prevent rebleeding or death at day 5) 
between the patients receiving rFVIIa compared to those receiving placebo.  
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Table 1: Prophylactic and therapeutic trials with rFVIIa in liver disease 
Study Study design Patients 
Number+ 
diagnosis 
Indication rFVIIa 
Doses 
Results Ref 
Jeffers  
2002 
Double-blind 
RCT 
No placebo 
66 patients 
Cirrhosis  
 
Laparo 
scopic  
liver  
biopsy 
5-120 
µg/kg 
Effect on 
INR and in 
74% on 
visible 
bleeding  
[168] 
Lodge  
2005 
Double-
blind, 
placebo-
controlled 
RCT 
204 patients 
Liver tumor 
Partial 
hepat-
ectomy 
20-80 
µg/kg 
 
x1-2 
No effect on  
transfusion 
requirement/ 
blood loss 
[169] 
Shao  
 2005 
Double-
blind, 
placebo-
controlled 
RCT 
235 patients 
Liver tumor 
+ cirrhosis 
Partial 
hepat-
ectomy 
50-100 
µg/kg 
 
x 1-4 
No effect on  
transfusion 
requirement 
[170] 
Lodge  
2005 
Double-
blind, 
placebo-
controlled 
RCT 
 
209 patients 
ESLD
2
 + 
cirrhosis 
 
Liver 
tx
3
 
60-120 
µg/kg 
  
 x 3 
Effect on 
number of 
patients 
requiring 
transfusion 
[171] 
Planinsic  
2005 
Double-
blind, 
placebo-
controlled 
RCT 
87 patients 
ESLD 
Liver  
tx 
20-80 
µg/kg 
No effect on  
transfusion 
requirement 
[172] 
Pugliese  
2007 
Double-
blind, 
placebo-
controlled 
RCT 
20 patients 
ESLD 
Liver 
tx 
40 
µg/kg 
Reduction in 
blood loss 
[173] 
Bosch 
2004 
Double-
blind, 
placebo-
controlled 
RCT 
245 patients 
Cirrhosis 
Upper   
GI
4
- 
bleeding 
100 
µg/kg 
Effect in 
subgroup 
CTP B-C 
on failure to 
control bleeding 
[174] 
Bosch 
2008 
Double-
blind, 
placebo-
controlled 
RCT 
265 patients 
Cirrhosis 
CTP B-C 
Upper   
GI- 
bleeding 
200 
µg/kg 
+ 100 
µg/kg 
x1-4 
No effect [175] 
 
 
  
                                                 
2
 ESLD= end-stage liver disease 
3
 Tx= transplantation 
4
 GI= gastrointestinal  
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rFVIIa in pediatric patients  
There are no randomized controlled trials in pediatric patients with liver diseases. Most 
of the published data on off-label rFVIIa use in children are case reports or reports from 
single centers or pooled data from registers [60, 176]. Alten et al. have reported the 
experience from the Childrens Hospital of Alabama 1999-2006, where 135 patients 
were treated with 997 doses of rFVIIa [177]. The median dose was 88 µg/kg (27-160 
µg/kg) and the patients had various conditions including DIC/sepsis, surgical bleeding, 
procedure prophylaxis, trauma, intracranial bleed etc. Thirty-six patients had hepatic 
dysfunction, 12 patients received rFVIIa on indication liver failure, 16 as procedure 
prophylaxis and 4 due to gastrointestinal bleeding. However data concerning these 
patients’ response to treatment are not presented in detail or separately discussed in the 
paper. Overall, it was stated that rFVIIa is associated with a significant decrease in 
blood transfusions when given to treat bleeding and that it may be effective as 
prophylaxis before invasive procedures. The authors express concern regarding the use 
of rFVIIa in children with disseminated intravascular coagulation due to high mortality 
in this group. Three patients developed thromboembolic complications.  
 
One large registry study from the Haemostasis Registry in Australia and New Zealand 
included 388 pediatric patients during 2003-2009, half of whom received rFVIIa in 
cardiac surgery [176]. Other clinical contexts were medical, other surgery than cardiac, 
hematology/oncology, trauma or intracranial hemorrhage. Only 2.8% received rFVIIa 
in association with liver disease. The median doses used were 114 µg/kg (range 7-2250 
µg/kg). The rate of thromboembolic events was 5.4%. The overall subjective estimate 
was that 82% showed a response in terms of bleeding and a significant reduction in the 
volume of transfused blood products 24 hours after treatment was shown. There was no 
association between the dose of rFVIIa and response or thromboembolic event.  
 
In the published case reports regarding rFVIIa in children with liver disease outcome 
data have shown a response rate between 54-100%, with a dose range of 26-300 µg/kg 
[60, 178-183].  
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1.7.6 Prothrombin complex concentrates (PCC) 
(Ocplex, Octapharma, Lachen, Switzerland and Confidex, CSL Behring, Marburg, 
Germany). The PCCs in use in Sweden contain the vitamin K-dependent coagulation 
factors FII, FVII, FIX, FX and inhibitors protein S and protein C and are referred to as 
4-factor PCC. Other PCC-products may contain a different combination of factors and 
inhibitors. PCCs available in the US contain very little or no FVII (3-factor PCC) [184]. 
PCC products are derived from plasma and are mostly used to reverse vitamin K 
antagonist treatment [185]. The other indications are bleeding or prophylaxis prior to 
surgery in patients with acquired or congenital deficiency of vitamin K dependent 
factors. There is limited information concerning its use in patients with liver disease. In 
an uncontrolled non-randomized trial, Lorenz et al. showed good efficacy of PCC in 
combination with endoscopic treatment in three patients with gastrointestinal bleeding 
and in 19 patients as prophylaxis prior to different invasive procedures. The product 
used did not contain protein S and additional treatment with antithrombin was used in 
five patients [186]. Data regarding treatment with PCC in children without congenital 
coagulation deficiencies are very limited and studies in pediatric patients with liver 
disease are lacking [187, 188].  
 
1.7.7 Octreotide  
(Sandostatin, Novartis, Basel, Switzerland) is not a hemostatic agent. It reduces portal 
pressure by lowering splanchnic vascular tone. A significant effect against variceal 
bleeding from has been proven in adults [189]. Octreotide has been evaluated in 
children with acute gastrointestinal bleeding and has shown good efficiacy and safety. 
In a retrospective trial by Eroglu et al., the response rate was 71%; however, 52% of the 
children experienced rebleeding. It is thus recommended to consider a combination of 
pharmacologic treatment and endoscopic intervention [190, 191]. There are other 
similar products on the market such as terlipressin but octreotide is the one most often 
used in the pediatric setting. 
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Anti-coagulant treatment 
 
1.7.8 Antithrombin  
(Atenativ, Octapharma, Lachen, Switzerland, and Antithrombin III, Baxter, Chicago, 
USA) is used to elevate the levels of the anticoagulant protein antithrombin in patients 
with congenital or acquired antithrombin deficiency. This product is increasingly used 
in infants and children with complex conditions, often in the intensive care setting, 
without congenital antithrombin deficiency [192]. The evidence for this treatment is 
still limited, though. Hardikar et al. evaluated the use of antithrombin concentrate in 
combination with fresh frozen plasma (FFP) and heparin postoperatively after liver 
transplantation in children. The purpose was to counter-balance the hypercoagulable 
condition that has been demonstrated in children during the early post-liver-transplant 
phase. A reduction in both thrombotic events and major bleeding was noted compared 
to historic controls [193].  
 
1.7.9 Low-molecular-weight heparin (LMWH )  
(Fragmin, Pfizer, New York, USA) potentiates the inhibitory effect of antithrombin on 
FXa and thrombin. It is routinely used as anticoagulant treatment in thromboembolic 
conditions in children [194]. The use of LMWH in cirrhotic patients with portal vein 
thrombosis or VTE seems safe and effective [195, 196]. Cirrhotic patients show an 
increased response to LMWH as measured by TGT [197]. Treatment with LMWH the 
day before percutaneous liver biopsy is a risk factor for bleeding complications in 
children [67]. The potential role of LMWH as an anti-fibrotic agent needs to be studied 
further [82]. 
 
1.7.10 Defibrotide  
(Gentium SpA, Villa Guardia, Italy) is a polydeoxyribonucleotide which acts at the 
endothelium. Different studies have shown several effects on the endothelium, 
including increased t-PA expression, reduced levels of PAI-1, inhibitory effect on 
tissue factor and a reduced expression of vWF [84].The product is not yet approved and 
clinical trials are ongoing. A recent large open-label randomized controlled trial 
regarding prophylactic treatment with defibrotide in pediatric hemopoietic stem cell 
transplantation showed a reduction in the incidence of VOD without any increase in 
bleeding complications [86]. Clinical reports, small trials and a phase II trial on 
treatment effects for severe VOD are also promising [84, 85]. Whether this substance 
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can have an impact in other types of liver disease or reduce fibrosis remains to be 
studied.  
Transfusion therapy 
 
1.7.11 Fresh frozen plasma (FFP)  
FFP contains the coagulation factors and inhibitors that normally occur in plasma. 
FVIII is, however, a heat labile protein and the levels are reduced by 24% within 24 
hours after the plasma has been thawed [198]. In a large retrospective epidemiologic 
study assessing the use of FFP in hospitalized children in the US, FFP was given in 
2.85% of the admissions [199]. That pediatric patients benefit from treatment with FFP 
has only been proven in the context of heart surgery, where patients who recieved FFP 
had a shorter stay in the intensive care unit compared to patients who received whole 
blood [200]. Randomized controlled trials in children regarding either massive 
hemorrhage or liver disease are missing. A retrospective analysis of 243 children 
undergoing liver transplantation at a single center showed that perioperative transfusion 
of FFP and red blood cell concentrates (RBC) were independent risk factors for patient 
and graft survival one year after the surgery [201].  
 
A volume of 1 ml fresh frozen plasma/ kg will theoretically increase the level of, for 
example the vitamin K dependent factors by 1 U/dL or 1% of normal adult level and 
10-15 ml FFP/kg is often administered in children [202]. The response to this treatment 
is, however, unpredictable, especially if the patient is bleeding. If the goal of the 
transfusion is to correct a coagulopathy much larger volumes might be needed [203]. 
Giving large volumes of plasma may, on the other hand, worsen the portal hypertension 
of a patient who has varicose veins and thus further, increase the bleeding, or provoke a 
bleeding in a stable patient [204]. Another complication that can occur when blood 
products are given at a high infusion rate or in large volumes is transfusion-associated 
circulatory overload (TACO). This condition has been described in adult patients and 
includes acute onset of dyspnea, hypertension, tachypnea and tachycardia, congestive 
heart and increase in brain-type natriuretic peptide. The condition is associated with 
high mortality [205]. In the expert pediatric opinion on the report from the Baveno V 
Consensus Workshop, the advice is to use plasma in acute variceal hemorrhage as 
general supportive care, but not with the goal of correcting clotting abnormalities [206]. 
There are several other adverse events associated with plasma transfusions, diagnosed 
in both adults and children. One is transfusion related acute lung injury (TRALI). In 
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TRALI the acute lung injury or acute respiratory distress syndrome (ARDS) occurs 
within 6 hours after transfusion [207]. The risk of transfusion-transmitted infections 
including hepatitis B, hepatitis C and HIV is minimal nowadays, but there is a potential 
risk from emerging infections [208].  
 
1.7.12 Platelet transfusion  
Platelet transfusion is used in patients with low platelet count and/or platelet defects, as 
prophylaxis prior to invasive procedures and in bleeding states. The British Committee 
for Standards in Haematology as well as the American Association for the Study of 
Liver disease (AASLD) have recommended a platelet count above 50-60 x 10
9 
prior to 
liver biopsy [209, 210]. These recommendations are mainly based on expert opinions 
and are also applied in pediatric literature [211]. However, a standard platelet dose in 
adult cirrhotic patients with thrombocytopenia did not increase the TGT result and the 
effect on thromboelastography was limited [212]. In patients with massive bleeding, 
higher ratios of platelets to red blood cell concentrates (RBC) have been recommended 
the past few years based on studies in trauma patients [213]. Similar guidelines are 
being discussed for pediatric patients [214]. An association between platelet 
transfusions during liver transplantation and increased mortality has been shown in 
adult, but not in pediatric patients [201, 215]. Data regarding the use of platelets in 
patients with liver disease are thus contradictory. Both TRALI and bacterial infections 
have been documented in patients who received platelet transfusions [207, 215].  
 
1.7.13 Red Blood Cell transfusions (RBC)  
An adequate hematocrit is important for oxygenation but also to drive the platelets 
towards the vessel wall, to be able to respond to a injury [216] . Overtreatment with 
blood transfusions may lead to volume overload and increased bleeding. A restrictive 
transfusion policy is regarded as safe and superior to a more liberal one and is 
recommended also in pediatric patients with bleeding from varices [206, 217]. The 
expert pediatric opinion on the report from the Baveno V Consensus Workshop 
recommends a target hemoglobin level between 7 and 8 g/dL [206]. An association 
between RBC transfusions and increased morbidity and mortality in adult patients 
undergoing liver transplantation has been described [218]. 
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2 AIM 
 
The overall objectives of the first part of the thesis were to improve the treatment and 
the analysis of coagulation defects in pediatric liver disease. The specific aims of the 
separate studies were to:  
 
1. investigate the clinical and biochemical effects of rFVIIa in the treatment of 
children with liver disease suffering from life threatening bleeding or as 
prophylaxis before invasive procedures. 
2. evaluate the value of thrombin generation test in addition to routine coagulation 
assays in children with liver disease compared to normal controls.  
evaluate the difference regarding thrombin generation test and routine 
coagulation tests between patients with standard bleeding risk versus those with 
increased risk. 
evaluate the effect on thrombin generation test of pro-hemostatic treatment in 
connection with liver disease. 
 
The overall objectives of the second part of the thesis were to improve the prognostic 
evaluation in liver disease. The specific aims of the separate studies were to: 
 
3. investigate if there is a correlation between fasting serum bile acids and 
coagulation factor levels in children with chronic liver disease.  
investigate whether increased levels of bile acids could influence the 
measurement of coagulation factor levels.  
 
4. assess the Owren-based INR reagents that are used in Scandinavia for analyzing 
INR values in patients with liver disease.  
determine the international sensitivity index (ISI) for these reagents in patients 
with liver disease and in patients on vitamin K antagonist treatment. 
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3 METHOD 
 
3.1 ETHICS 
The Ethics committees of the Karolinska Institutet approved all the study protocols. 
The Ethics committee of Linköping University approved the protocols concerning 
enrollment of the patients at Linköping University Hospital in Study 4. Informed 
consent was obtained from all patients and the children who served as normal healthy 
controls and/or their parents.  
 
3.2 PATIENTS (ALL STUDIES) 
Patients at the tertiary center for pediatric hepatology at Karolinska University Hospital 
were enrolled in study 1-3. In study 4 we recruited adult patients, instead of children, 
due to the required larger sample volume. These patients were included at the 
Departments of Gastroenterology & Hepatology at Karolinska University Hospital and 
Linköping University Hospital. 
Age: The mean age in years and age-range of the patients in the different studies were: 
Study 1, 6.8(0.2-15.9); Study 2, 13.4(1.2-20.5); Study 3, 7.7(0.2-18.8); Study 4, 
57.8(16.6-80.0) 
Diagnoses: In Study 1-3 the predominant groups of liver diseases were: abnormal 
development, inborn errors of metabolism and immune mediated liver diseases.  
In Study 4 the predominant groups of liver diseases were: infection and xenobiotic – 
induced liver disease (alcohol induced liver cirrhosis).  
Prognostic scoring systems: The PELD scores in Study 3 were in median -7 (range 
-11:22). In Study 4 the MELD score was in median 16 (range 8-40) and the number of 
patients with CTP class A was 15, class B 16 and class C 30 patients.  
Normal healthy controls: The children who served as healthy normal controls in 
Study 2 were patients planned for ear, nose or throat surgery at the ENT department of 
the same hospital. In study 4 anonymous plasma samples from healthy controls and 
redundant plasma from patients on oral anticoagulation were used for the ISI-
determination. These samples were collected at Linköping University Hospital for the 
purpose of calibrating hospital laboratory instruments.  
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3.3 METHODS (ALL STUDIES) 
 
Laboratory assays:  
 
Setting: In Study 1-3 the laboratory assays were performed at Karolinska University 
Laboratory in study 1-3.The different hospital laboratories involved in Study 4 are 
shown in Table 2. 
 
Blood collection: Blood was collected into citrated vacutainer tubes and centrifuged at 
2000x g for 15 minutes prior to all coagulation assays in study 1 and 3-4. In study 2, the 
blood samples were double centrifuged at 2000x g for 15 minutes prior to the specific 
coagulation assays and the thrombin generation assay. The citrate concentration in the 
tubes was 0.129 mol/L trisodium citrate in study 1, 3 and the assessment study of study 
4. The additional samples taken for the ISI project of Study 4 as well as in study 2, 
were collected in vacutainer tubes with 0.105 mol/L, due to an overall change in the 
Swedish laboratory standard in order to adhere to WHO guidelines. The difference in 
INR between samples with these two citrate concentrations is below 2% according to 
an evaluation performed by the External Quality Assurance of Laboratory medicine 
(EQUALIS) in Sweden (unpublished data).  
 
Routine coagulation tests: The prothrombin time method according to Owren was 
used in all studies. INR was not established at Swedish laboratories at the time of 
sample collection in Study 3. Instead, the results were given as prothrombin time in 
percent of normal activity (PT%) and to obtain the results in INR the data were 
recalculated according to the formula INR = (1/PT%+0.018)/0.028 [219]. The reagent 
SPA (Diagnostica Stago, Paris, France) was used in study 1 and 3 and SPA+ 
(Diagnostica Stago) was used in study 2 and for the analyses performed at the 
Karolinska University Laboratory in Study 4. In fact, both mean SPA and SPA+ were 
evaluated in the assessment study, Study 4, but only the results obtained with SPA+ are 
given in the manuscript since the mean difference between the results was 1.1% and 
SPA is no longer in use. Fibrinogen was analyzed according to the Clauss method with 
two different reagents in Study 4 plus an additional reagent in Study 2. However ,the 
reference ranges were equivalent and differences between reagents with this method are 
low [220]. APTT was included the study protocol in Study 2.  
 
 36 
Specific coagulation assays: FII, FV, FVII and FX were analyzed in Study 2-4, FIX 
was analyzed in Study 2 and 3. Chromogenic methods were used for FII, FVII, and FX 
in the clinical part of Study 3, however, these were replaced by one-step clotting assays 
when the other studies were performed. The reference ranges remained unchanged 
despite the change in methods. The anticoagulant factors protein C, free protein S, and 
antithrombin were measured in Study 2. Detailed information concerning the reagents 
and instruments used is provided in each manuscript. Fluorogenic computerized 
thrombin generation test (CAT) according to Hemker was performed in Study 2.  
 
 Liver function tests: Baseline liver function tests results obtained according to 
hospital routine are provided in each manuscript of Study 2-4. These include serum 
concentrations of ALT, bilirubin, albumin and fasting bile acids in Study 2-3 and 
bilirubin and albumin in study 4.  
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3.4  STUDY 1-2 
3.4.1 Patients and methods: 
 
Study design: Study 1 was a prospective, open, uncontrolled clinical trial and Study 2 
was a prospective cross-sectional observational study. 
In study 1 children with liver disease received rFVIIa on indication life threatening 
bleeding and failure of conventional therapy or prior to invasive procedures as 
prophylaxis.  
In study 2 patients with liver disease with or without increased bleeding risk were 
enrolled. Increased bleeding risk was defined by at least one of following; INR >1.4, 
APTT >44 sec., fibrinogen <1.5g/L or overt bleeding. Thrombin generation assay, 
routine coagulation tests and specific pro- and anticoagulant factors were analyzed. For 
patients undergoing liver biopsy with or without pro-hemostatic treatment follow-up 
analyses were performed.  
 
Bleeding: Seven patients in Study 1 received rFVIIa on 22 occasions on indication life 
threatening bleeding including, gastrointestinal bleeding, epitaxis and bleeding into 
cholecystostomy. On five occasions rFVIIa was given before different procedures 
related to bleeding. Three of the patients in the “increased bleeding risk” group had 
overt bleeding from the gastrointestinal tract. 
 
Liver biopsy: Six patients in Study 1 and 74 patients in Study 2 underwent 
percutaneous liver biopsy on clinical indication, under general anesthesia. In the 
transplanted patients the biopsy was carried out under real-time ultrasound guidance. In 
Study 1, transjugular biopsy technique was used in two patients.  
 
Pro-hemostatic treatment: In Study 1 rFVIIa was given as intravenous bolus doses of 
34-163 µg/kg, with 1-3 doses/patient on indication bleeding or as prophylaxis prior to 
invasive procedures.  
In Study 2, three patients received single rFVIIa doses of 71-90 µg/kg on indication 
elevated INR prior to liver biopsy. Desmopressin 0.3 µg/kg was administered to nine 
patients due to prolonged template bleeding time prior to the invasive procedure. In 
nine patients, additional treatment with tranexamic acid was given.  
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Follow-up evaluation after invasive procedure and/or treatment:  
 
Clinical outcome: In Study 1 the vital signs and serious events within 48 hours were 
registered as well as thromboembolic complications, transplantation and death within 2 
weeks. The effect on bleeding from treatment was based on visual inspection (if the 
bleeding source was visible), changes in hemoglobin and need for blood transfusions. 
In Study 1 and 2 bleeding symptoms after liver biopsy were recorded. In Study 2 signs 
of bleeding post liver biopsy were stated as tachycardia, reduction in blood pressure, 
reduction in hemoglobin of more than 20 g/L and the need for blood transfusion.  
 
Laboratory outcome: In both studies hemoglobin was checked 24 hours after the 
biopsy and as needed if there were clinical signs of bleeding. INR was analyzed before, 
1, 4, 12 and 24 hours after treatment with rFVIIa in Study 1. In Study 2, samples were 
obtained before and 4 hours after treatment for thrombin generation test including ETP, 
LT, peak height and TTP.  
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3.5 STUDY 3-4 
3.5.1 Patients and Methods 
 
Study design: Both studies were prospective cross-sectional observational studies with 
an additional laboratory study each.  
In Study 3 the patients were divided into two groups, those with FSBA below and 
above 200µmol/L, respectively, and the correlation between FSBA and the coagulation 
factors was analyzed in each group. In the laboratory study, increasing amounts of bile 
acids were added to normal plasma and FII, FV, FVII and FX were measured in the 
different bile dilutions.  
In Study 4 plasma from patients with liver disease was sent to eight different hospital 
laboratories and analyzed for Owren based INR with the local INR reagent to 
determine the interlaboratory variance. In the laboratory study the ISIliver and the ISIVKA 
and were determined according to the WHO protocol for the reagents included in the 
assessment study. The difference between these ISI values was determined.  
 
Owren based reagents: Nycotest PT, (Medinor, Stockholm, Sweden), Owrens PT 
(Medirox) and SPA+ (Diagnostica Stago) were used in both the assessment study and 
the ISI study (Table 2).  
 
Table 2: The hospital laboratories involved in Study 4. 
Laboratory Hospital Reagent 
Lab1 Karolinska SPA+, Diagnostica Stago 
Lab2 Malmö SPA+, Diagnostica Stago 
Lab3 Sahlgrenska SPA+, Diagnostica Stago 
Lab4 Linköping Owrens PT, Medirox  
Lab5 St Göran Owrens PT, Medirox  
Lab6 Örebro Nycotest PT, Medinor 
Lab7 Falun Nycotest PT, Medinor 
Lab8 Växjö Nycotest PT, Medinor 
 
 
ISI determination: The WHO protocol was used to determine the ISIVKA for each 
reagent [36]. Within this protocol plasma from 60 Warfarin treated patients and 20 
normal controls are analyzed with the reference thromboplastin RBT/05 with an ISI of 
1.15 (NIBSC, Potters Bar, England [221]) and the manual tilt-tube technique. The 
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ISIliver was determined with the same procedure, except for the plasma, which in this 
setting, was plasma from the included patient with liver disease patients and 20 normal 
controls. This alternative calibration procedure for patients with liver disease was first 
described by Bellest et al. and Tripodi et al. [100, 101]. These analyses were performed 
at Linköping University Hospital. 
 
 
3.6 STATISTICS (ALL STUDIES) 
Study 1 was a descriptive study. All results from Study 2-4 were entered into the 
statistics software Statistica, release 10 (StatSoft Scandinavia, Uppsala, Sweden). 
Mann-Whitney’s test was used in all these studies for comparison between groups since 
the distributions were skewed. A P value of <0.05 was considered statistically 
significant. Spearman’s rank correlation was used to obtain correlation coefficients. 
The difference in parameters before and after liver biopsy in Study 2 was calculated 
and compared to the difference in patients undergoing the same procedure without 
treatment or bleeding within the same age group. Coefficients of variation were 
calculated as CV= (SD/mean x 100), in both the in vitro study in Study 3 and in the 
assessment study in Study 4. Calculations of ISI and CV of slope were done using 
Excel (Microsoft) and Sigma plot 10 (Systat software, Port Richmond, CA, USA).  
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4 RESULTS 
4.1 STUDY 1-2: 
 
4.1.1 Baseline laboratory tests:  
The median INR prior to treatment in Study 1 was 1.88 (range 1.04-6.0) in the group 
with life threatening bleeding and 1.52 (range 1.08-2.85) in the prophylaxis group. 
The patients with liver disease in Study 2 had higher levels of vWF and FVIII and 
shorter LT and TTP compared to normal controls. The 71 liver patients with standard 
risk of bleeding had an ETP similar to normal controls. The 11 patients with an 
increased bleeding risk had a reduced ETP, compared to standard risk patients, 
concordant with their results of the routine coagulation tests. These patients had also 
reduced levels of procoagulant factors (II, VII, IX, X and for adolescents also V and 
fibrinogen) and concomitant lower levels of anticoagulant factors such as antithrombin 
and protein C. Thus the thrombin generation assay did not provide additional 
information regarding the balance between pro- and anticoagulant factors in children 
with liver disease compared to routine coagulation tests.  
The ETP increased with increasing age in both the patients with liver disease and the 
normal controls (Figure 5). 
 
 
 
Figure 5: The correlation between the age and ETP in all patients in Study 2.  
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4.1.2 Effect of pro-hemostatic treatment  
 
Bleeding: rFVIIa was administered on 22 occasions in Study 1. The bleeding decreased 
in ten of these cases and remained unchanged in seven and increased in two. The 
treatment could not be evaluated on three occasions. In the two patients who had an 
increased bleeding, the preceding treatment with Octreotide was interrupted before the 
treatment with rFVIIa was initiated. A combination of Octreotide and rFVIIa was 
successful on eight of fourteen occasions. Additional treatment with fresh frozen 
plasma was given on three occasions. 
 
Invasive procedures: rFVIIa was given before different therapeutic invasive 
procedures, related to bleeding, on five occasions in Study 1. The procedures were 
dilatation of a portal vein stenosis on two occasions and endoscopic sclerotherapy or 
ligation on three occasions. The last event was combined with Port-á-Cath placement 
and hip arthrocentesis. On all these occasions the bleeding stopped with the 
combination of rFVIIa and the procedure.  
rFVIIa was also given on nine occasions as prophylaxis prior to liver biopsy in Study 1 
and on three occasions in Study 2. These patients had all an expected increased 
bleeding risk, however, none of them experienced any bleeding complication. 
Additional treatment with desmopressin was given in two cases and fresh frozen 
plasma in one case in Study 1. In Study 2 the rFVIIa treatment was combined with 
tranexamic acid in two patients. Another eight patients in Study 2 underwent liver 
biopsy after prophylactic treatment with desmopressin, which was combined with 
tranexamic acid on seven occasions.  
 
4.1.3 Laboratory evaluation:  
The patients in Study 1 responded to the rFVIIa treatment with a clinically relevant 
reduction in INR in samples collected within 1-4 hours after rFVIIa was given. The 
effect was transient and on ten of the treatment occasions INR values above baseline 
were noted at follow-up 12-24 hours after the treatment. In Study 2 the rFVIIa treated 
patients had a significant decrease in LT and TTP compared to the untreated patients, 
however, the effect on ETP and peak height was inconclusive. In the patients who 
received desmopressin the reduction in peak height and the increased TTP after the 
biopsy were not as pronounced as in the normal controls. The ETP and LT were not 
significantly influenced by desmopressin treatment.  
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4.1.4 Serious events:  
One 8-year-old girl in Study 1 had a portal vein thrombosis detected on 
ultrasonography after three doses of rFVIIa, however, this could not be verified on CT-
scan 6 hours later or at liver transplantation 2 days later. This patient and two other 
patients in the bleeding group of Study 1, who received multiple doses of rFVIIa and 
had very severe liver disease, developed multiorgan failure and died within 1-14 days 
after their last dose of rFVIIa. In Study 2 neither thrombosis nor multiorgan failure was 
seen after pro-hemostatic treatment.  
None of the patients who underwent liver biopsy experienced any bleeding 
complication with a decrease in hemoglobin exceeding 20 g/L. 
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4.2 STUDY 3 
 
4.2.1 Clinical data  
In the 12 children with FSBA above 200 µmol/L there was a significant positive 
correlation between FSBA and FV, FVII and prothrombin time (Figure 6). There was a 
significant negative correlation between FSBA and INR (Figure 7). Conversely, in the 
33 patients with FSBA under 200 µmol/l, significant negative correlations between 
FSBA and FVII and FIX were seen. The patients with bile acids above 200 µmol/l had 
a significantly worse outcome than patients with lower levels of bile acids.  
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Figure 6-7: The relationship between FSBA and the levels of FVII and INR, 
respectively. 
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4.2.2 Laboratory study:  
We observed no interference between bile acids and coagulation factors in the 
laboratory study (Table 3.).  
 
 
 
 
Table 3: Serum bile acid levels and coagulation factor levels after in vitro addition of 
increasing amounts of bile acids. 
Taurocholic acid  
and/or normal plasma 
S-bile acids 
  (μmol/l) 
FII 
(kIE/L) 
FV 
(kIE/L) 
FVII 
(kIE/L) 
FX 
(kIE/L) 
INR Albumin 
(g/L) 
Sample 1 386 0.96 1.14 0.95 0.92 0.96 30.9 
Sample 2 193 0.90 1.20 0.98 0.92 0.96 30.6 
Sample 3 69 0.90 1.18 0.99 0.91 0.96 31.9 
Normal plasma 3.6 0.85 1.19 0.99 0.92 0.96 30.7 
Glycocholic acid  
and/or  normal plasma 
S-bile acids 
  (μmol/l) 
FII 
(kIE/L) 
FV 
(kIE/L) 
FVII 
(kIE/L) 
FX 
(kIE/L) 
INR Albumin 
(g/L) 
Sample 1 467 0.93 1.18 0.97 0.88 0.96 31.0 
Sample 2 198 0.90 1.13 0.98 0.92 0.96 30.9 
Sample 3 62 0.84 1.16 0.96 0.92 0.99 30.8 
Normal plasma 3.8 0.90 1.23 0.97 0.93 0.96 30.8 
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4.3 STUDY 4 
 
4.3.1 Assessment study 
The mean difference between the highest and the lowest reported INR was 0.31 (range 
0.13-0.86) for all 20 patients (Figure 8). The coefficient of variance for the Owren 
based INR methods at the hospital laboratories was 5.3% in average, which is low 
compared to previous studies [96, 97] 
 
 
 
Figure 8: The reported INR for each patient from each laboratory. 
 
4.3.2 ISI-study 
All Owren based reagents had a difference between ISIVKA and ISIliver below 10% 
(Table 4).  
 
 
 
Table 4: The obtained ISI for each reagent. 
Thromboplastin Instrument ISIvka ISI liver % Diff ISI vka-liver
5
 
Owren-method         
SPA+ ACL Top 1.01 1.00          0.7 
Owrens PT ACL Top 1.23 1.14          7.1 
Nycotest PT ACL Top 1.08 1.05          3.4 
 
                                                 
5
 The percentage difference between ISIVKA and ISIliver. 
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5 DISCUSSION AND FUTURE PERSPECTIVES 
 
5.1 STUDY 1-2 
 
5.1.1 Balance in liver disease and in children 
The balance between pro- and anticoagulant factors is maintained in patients with liver 
disease. However, this balance seems to be unstable due to the lower levels of both the 
pro- and anticoagulant factors [131]. Although it is the bleeding symptoms that 
predominate in the clinical setting, the association between fibrosis and 
hypercoagulation, as well as the occurrence of thromboembolic events in adult patients 
are increasingly discussed [222-224]. Factors that may tip the balance in either 
direction include infections, inflammatory conditions, hereditary bleeding or 
prothrombotic disorders, massive gastrointestinal bleeding, volume overload and renal 
failure [63, 64, 79, 206, 222, 225, 226]. The coagulation system of healthy children also 
maintains a different balance compared to that of healthy adults. Higher levels of vWF, 
FVIII and lower levels of vitamin K-dependent factors and inhibitors are also seen in 
infants and neonates [46]. The physiological plasma concentrations of coagulation 
factors change during infancy and childhood before reaching the levels of adults [45, 
46]. The risk of thrombosis is lower in children than in adults, without an increase in 
bleeding risk [58, 227]. On the other hand, bleeding and thrombosis do occur children 
with disease states including; infections, inflammatory states, malignancies, hereditary 
bleeding or prothrombotic disorders, renal failure and liver disease [47, 58, 176, 177, 
228]. The etiologies of the pediatric liver diseases are different from those in adults [3]. 
It is, thus necessary to perform studies regarding coagulation specifically in children 
with liver disease. 
 
5.1.2 Treatment of overt bleeding 
Important means of treating bleeding episodes from varicose veins are the use of 
antibiotics against infections that aggravate the bleeding, and octreotide to reduce portal 
flow [65, 66, 191]. Octreotide is known to be effective in about 70% of the patients, but 
non-responders require additional treatment [190]. We could show in Study 1 that the 
addition of rFVIIa to the treatment with octreotide may be successful in these patients 
and that rFVIIa may help stabilize the patient and give us extra time to perform 
diagnostic or therapeutic procedures.  
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Large randomized controlled trials in adults have not proven any effect of treatment 
with rFVIIa in terms of stopping bleeding from varicose veins [174, 175]. On the other 
hand, in children clinical reports and small studies, including ours, have been more 
promising [60, 176-183]. Thus, specific large randomized trials for children with liver 
disease and severe gastrointestinal bleeding symptoms are needed.  
 
5.1.3 Prophylactic treatment 
As evidence accumulates regarding the balance between pro –and anticoagulant 
mechanisms, the general practice of routinely giving preoperative treatment in order to 
correct coagulopathy prior to invasive procedures is being questioned [131]. However, 
with the lack of controlled trials evaluating preoperative treatment against no treatment, 
most recent published recommendations are still advocating platelet count above 50-60 
×10
9
 [209, 210] and INR below 1.5 [211, 229, 230], both in adults and children. We 
evaluated rFVIIa as prophylactic treatment in patients with an elevated INR above 1.4 
prior to invasive procedures and none of the patients experienced any bleeding 
complication. rFVIIa can, thus be used in these children with liver disease when 
prophylaxis is considered indicated. An advantage with the use of rFVIIa might be the 
product’s half-life which is short, and particularly short in children [163]. Thus, the 
duration of an expected tip towards a more hypercoagulable condition induced by the 
treatment, is theoretically very limited.  
 
5.1.4 Balance and future treatment strategies 
The incidence of multiorgan failure and the high mortality rate in our study are 
primarily considered to have been caused by the severe condition of the children 
receiving this treatment. Alten et al. have had similar experience [177]. Nonetheless, 
the potential risk of adverse events needs to be considered. Multiple doses of rFVIIa 
should be avoided, if possible, and special attention must be paid to concomitant low 
levels of anticoagulant factors. In many publications the advice is to avoid hemostatic 
treatments in patients with liver disease and to administer pro-hemostatic agents only if 
a bleeding episode necessitates “rescue therapy” [204, 231, 232]. However, some of the 
children with severe liver failure are in such a severe clinical condition and their 
hemostatic balance is so unstable that it could be deleterious to perform an endoscopic 
procedure under general anesthesia to stop a variceal bleeding. In these patients, with 
depleted levels of both pro- and anticoagulant factors, with an obvious bleeding 
tendency and concomitant slow portal flow, a pragmatic way to prevent severe bleeding 
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or thrombus formation would be substitution with both pro- and anticoagulant factors in 
risk situations and prior to invasive procedures. This regimen would theoretically 
maintain the balance, but at a higher level and closer to or within age-specific ranges. 
Hemostatic treatments for this purpose would include a combination of fibrinogen 
concentrate, antithrombin, 4-factor PCC including protein S and protein C and possibly 
platelets. Routine coagulation tests (including fibrinogen, antithrombin, INR and 
platelet count) and perhaps TGT could be used to guide this treatment. The use of 
factor concentrates instead of plasma would decrease the risk of volume overload and 
the risk of transmitting infections. If this treatment fails and variceal bleeding leads to 
medical emergency, both octreotide and tranexamic acid, as well as rFVIIa should be 
considered. Although expensive, this treatment strategy might save the lives of patients 
with a severe condition. However, this proposed treatment strategy still needs to be 
evaluated in clinical trials. A combination of a modified bleeding risk score and 
coagulation tests might be useful to select the right patients.  
 
5.1.5 Thrombin generation  
In view of the uncertainty regarding which laboratory assays are best at helping the 
clinician find patients at high risk for bleeding or thrombosis or both, and personalize 
treatment on that basis, we evaluated TGT in Study 2. However, this commercially 
available assay did not provide other information than routine coagulation tests. The 
patients with an increased bleeding risk according to routine coagulation tests had 
reduced levels of the procoagulant factors (II, VII, IX, X and for adolescents also V and 
fibrinogen), as well as the anticoagulant proteins (antithrombin, protein S and C). The TGT 
showed a reduction in ETP, as expected from the routine tests; however, it did not provide 
additional information regarding the suspected counteracting effect of the anticoagulant 
proteins. TGT with the addition of thrombomodulin might provide more information 
concerning the balance of the coagulation system, due to the activation of the protein C 
system [118]. However, TGT with thrombomodulin has not been shown to predict 
bleeding or thrombotic events in the clinical setting [117]. This might be explained by 
the fact that the bleeding occurs irrespective of the coagulation status, but it may also 
be that the assay is not sensitive enough to detect a disturbed hemostatic balance.  
Study 2 also shows that many of the patients in this cohort, with a clinical need for liver 
biopsy, have normal coagulation tests as compared to healthy children, except for the 
increase in the levels of vWF and FVIII. These patients were regarded as “standard risk 
group” in this study. Healthy children generally have a lower risk of thrombosis than 
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adults, without an increased bleeding risk [227]. These differences are probably of 
importance in children with compensated liver disease, as well. The levels of ETP 
increased with increasing age in the patients in the standard risk group, similarly to the 
healthy controls.  
 
5.1.6  Studies in children – limitations 
Researchers attempting coagulation studies in the pediatric population encounter 
several difficulties. It is often difficult to obtain samples from children and small 
needles including butterfly needles are frequently used, which increase the risk of pre-
analytical errors[27]. This was the reason we chose the 5 pM tissue factor concentration 
in Study 2, instead of the 1 pM reagent. The 1 pM reagent is known to be more 
sensitive both to coagulation defects and to pre-analytical errors [28, 229]. We also 
avoided TGT with platelet-rich plasma and the platelet function assays in this study for 
several reasons, including; difficulties interpreting the results owing to the interference 
caused by thrombocytopenia, the requirement for large sample volumes and sensitivity 
to pre-analytical conditions [52]. In this thesis only template bleeding time was used to 
evaluate the platelet function, despite the assay’s poor reproducibility. However, only a 
few, experienced and well trained nurses of the staff at our department are certified to 
perform this test, which helps limit this problem. Development of better platelet 
function assays is warranted as this would enable us to perform important studies 
regarding the platelet function in children with liver disease. Improved assays would 
also make it possible to assess the use of treatment with desmopressin in patients with 
liver disease. There is also a need for assays validated in children for the evaluation of 
the fibrinolytic system and endothelial function.  
 
Although age-specific reference ranges for coagulation assays used on children are of 
clinical and scientific importance such data are scarce. We enrolled healthy children as 
controls in Study 2 because at that time, there were no reference ranges for the 
combination of instruments and reagents we intended to use. The collection of blood 
samples from healthy children is time consuming, and costly in terms of both money 
and personnel, and there are also ethical considerations. It is thus unrealistic to expect 
each laboratory to develop its own reference ranges for children. It will probably be 
necessary to offer incentives similar to those aimed to encourage pharmaceutical 
companies to perform clinical trials in children. Collaboration between manufactures of 
laboratory equipment and large pediatric centers could be a way to provide age-specific 
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reference ranges as new assays are developed. Companies that offer such collaboration 
should be favored when laboratory equipment is being procured.  
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5.2 STUDY 3-4 
 
5.2.1 Severe cholestasis and coagulation 
Coagulation factor levels are thought to decrease and INR, PELD, MELD and CTP 
scores to increase as liver function deteriorates, irrespective of the etiology. This is the 
rationale behind using these analyses and scores for assessment of liver function, 
prognosis and liver allocation. However, there are reports showing that the PELD score 
underestimates mortality in children with liver disease, and previous studies have 
indicated a hypercoaguble state in patients with cholestatic liver disease of adulthood, 
including primary biliary cirrhosis and sclerosing cholangitis [126, 230, 233]. In Study 
3, we, thus wanted to investigate the levels of coagulation factors in children with 
cholestasis. We chose the patients with the highest fasting bile acid concentrations (i.e. 
those in whom bile acids exceeded 200 µmol/L) since in clinical practice, their 
condition is most severe and they are the patients most likely to be evaluated as 
candidates for liver transplant. It has been demonstrated that levels between 10-100 
µmol/L do not differentiate between hepatocellular and cholestatic liver damage [234]. 
We could show that the patients in the high FSBA group had a worse outcome due to 
liver failure, and although they were regarded as being more seriously ill, their INR was 
not worse (i.e. not higher) than would have been expected. On the contrary, this study 
shows that when the FSBA are above 200 µmol/L the coagulation factor levels do not 
reflect the severity of the liver disease since increasing levels of bile acids are 
correlated to increasing levels of coagulation factors and decreasing INR.  
 
5.2.2 In vitro evaluation 
To exclude that the bile acids had a direct effect on the performance of the coagulation 
factor assays that could explain these results, we added tauro- and glycocholic acids to 
samples with normal plasma and measured the INR and coagulation factor levels. The 
bile acids chosen were the ones which occur most abundantly in plasma and the levels 
used were relevant for this patient group. The bile acids did not have any detectable 
effect on pro-coagulants in vitro in this study. 
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5.2.3 Mechanism and implication 
Bile acids can activate the nuclear farnesoid X receptor in human hepatoma cells and 
activation of these receptors induces an increased fibrinogen expression [115]. This 
potential link between bile acids and the expression of coagulation factors needs to be 
further explored. We have initiated a study where the mRNA expression of such factors 
in liver biopsies before and after bile diversion is analyzed. Bile diversion is a well 
established method to decrease the serum concentrations of bile acids in patients with 
progressive familial intrahepatic cholestasis [235].  
It is also important to evaluate if the increase in procoagulant factors in patients with 
high levels of bile acids is counteracted by a similar increase in the levels of the 
anticoagulant factors including antithrombin, protein C and protein S, or if a 
hypercoaguable condition is present, as described in adults with cholestasis [126, 233]. 
Thus, there might be an increased need for anticoagulant prophylaxis in conditions 
associated with an increased risk of thrombosis in children with highly elevated levels 
of bile acids. However, our study, revealed increased risk of both bleeding and 
thrombosis in the high FSBA group compared to the low FSBA group. Although the 
number of patients was small and the differences not statistically significant, this would 
indicate an unstable coagulation system in these patients. It is essential to further 
explore these issues since a majority of the pediatric patients evaluated for liver 
transplantation in fact have a cholestatic condition [8].  
 
5.2.4 INR in liver disease 
The use of INR as a coagulation screening test as well as for prognostic purposes in 
patients with liver disease highlights the need for a robust method with a low 
variability. The INR according to the Quick method has not been able to fulfill these 
requirements [102]. The INR system according to both Quick and Owren was 
developed for patients on VKA treatment with the purpose of evaluating the treatment 
effects on FII, FVII and FX [34, 35]. The result of the Quick assay is dependent on 
these factors, but also on FV and fibrinogen. The last two factors are, assumed to be 
normal in the VKA treated patients [70]. In patients with liver disease, however, the 
levels of all of these factors – including FV and fibrinogen – are often reduced, though 
fibrinogen levels can sometimes be elevated. This discrepancy between the coagulation 
defects seen in patients undergoing VKA treatment and in patients with liver disease 
might explain the larger interlaboratory variance in samples from patients with liver 
disease compared to those from VKA treated patients analyzed with this method. In 
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Scandinavia, the Owren method is used which only depends on the levels of FII, FVII 
and FX. These factors are similarly affected by VKA treatment and by liver disease. In 
the assessment study of Study 4, we showed that the Owren method had a low 
interlaboratory variability, when samples from patients with liver disease were sent to 
eight Swedish hospital laboratories. In the ISI study of Study 4, we could show that the 
calibration system, developed for patients on VKA treatment, could also be used for 
patients with liver disease.  
A limitation of the study was that the samples were collected in tubes with different 
citrate concentrations in the assessment part of the study and during the inclusion of 
additional patients for the ISI study. However, the difference in INR between samples 
collected at these two concentrations is minimal.  
 
5.2.5 The Owren method and scoring systems 
Several scoring systems – including the PELD, MELD and CTP scores – have been 
developed in countries that use the Quick method [136, 137]. There might be a concern 
that FV and fibrinogen could be of importance for the evaluation of patients with liver 
disease and that these scores might be inappropriate if these two factors are excluded 
from the assay, as they are in the Owren method. However, it can be argued that INR 
has been used for several years as a liver function test and prognostic factor in 
Scandinavia and that the Quick method’s high interlaboratory variability is a bigger 
problem. A study comparing the prognostic value of PELD and MELD in centers using 
the Quick method and centers using the Owren method would be worthwhile to further 
evaluate this issue.  
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6 CONCLUSIONS 
 
1. rFVIIa is beneficial in some patients in the short term management of life 
threatening bleeding in severe liver disease. 
rFVIIa can be used as prophylaxis before various diagnostic and therapeutic 
procedures in children with liver disease and coagulopathy. 
 
2. Measurement of thrombin generation with current assay does not provide 
additional information regarding the hemostatic function in children with liver 
disease compared to routine coagulation tests. 
3. Positive correlations were found between fasting serum bile acids and 
coagulation factors in patients with bile acids levels exceeding 200µmol/L, 
despite a worse clinical outcome. Coagulation factors may be questionable as 
prognostic markers in patients with markedly elevated bile acids. 
Increased levels of bile acids did not influence the measurement of coagulation 
factor levels. 
 
4. Interlaboratory variation in INR analyses in chronic liver disease was low using 
Owren-based methods.  
The differences between ISIVKA and ISIliver for the studied Owren reagents were 
below 10%. ISIVKA for Owren reagents can be used in the INR calibration when 
analyzing plasma from patients with liver disease. 
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7 DIRECTIONS FOR FUTURE RESEARCH 
 
To improve the treatment and the analysis of coagulation defects in pediatric liver 
disease; 
 
 Explore differences in coagulation mechanisms in children compared to adults, 
with or without liver disease, including the clot formation.  
 Further development and clinical assessment of global as well as platelet 
function assays.  
 Evaluation of TGT with thrombomodulin in the clinical setting including the 
predictive value of this assay regarding bleeding and thrombosis.  
 Develop a modified bleeding risk score for children with liver disease. 
 Clinical multicenter trials regarding combined treatment with pro- and 
anticoagulant coagulation factor concentrates in children with severe liver 
disease. 
 
To improve prognostic evaluation in liver disease 
 
 Investigate the mechanisms by which bile acids can affect the levels of 
coagulation factors, possibly in animal models. 
 Investigate the impact of bile diversion on the mRNA expression of coagulation 
factors in liver tissue. 
 Investigate the outcome of patients with high bile acids (including patients with 
PFIC, without bile diversion) in a PELD based liver allocation system. 
 Compare the prognostic value of PELD and MELD in centers for pediatric 
hepatology that use the Quick method versus the Owren method, or run the two 
methods in parallel in a multicenter study.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Levern är ett av kroppens största organ. Den har stor betydelse för ämnesomsättning, avgiftning 
av blodet och produktion av olika proteiner, bland annat de som behövs för att kunna levra 
blodet.  
Varje år insjuknar ungefär 100 barn i Sverige i allvarlig leversjukdom. Åldern vid insjuknandet 
kan variera från nyföddhetsperioden till 18 års ålder. Ungefär 10-15 av dessa behöver genomgå 
levertransplantation, medan många kan räddas till livet med annan behandling. 
Denna avhandling är inriktad på leverns förmåga att tillverka blodlevringsfaktorer. 
Tillverkningen av dessa minskar ofta vid leversjukdom och flera barn med leversjukdom 
drabbas av svåra blödningar. Blödningarna förekommer framför allt i näsa och mag-tarmkanal 
och kan vara livshotande och svårbehandlade.  
 
Studie 1 
I den första studien studerades effekten av en ny typ av behandling mot de här blödningarna, 
nämligen konstgjort framställd blodlevringsfaktor VII. Vi såg att preparatet är värdefullt som 
akutbehandling och ger en möjlighet att kunna gå vidare med mer specifika behandlingar mot 
blödningskällan.  
 
Flera av barnen behöver genomgå olika typer av ingrepp även i lugnt skede. Ett sådant vanligt 
ingrepp är att man med nål tar ett litet vävnadsprov från levern och analyserar i mikroskop för 
att kunna se vilken typ av leversjukdom barnet lider av. Detta ingrepp är förknippat med 
blödningsrisk och man vågar därför inte alltid göra detta på barn med påverkan på 
blodlevringssystemet. Vi har på grund av detta provat att ge faktor VII preparatet till just dessa 
barn innan ingreppet och sett att vi på så sätt kunnat undvika blödningskomplikationer. Detta 
har förbättrat diagnostiken för dessa barn.  
 
Studie 2 
Alla barn med leversjukdom blöder inte, en del kan till och med drabbas av motsatsen, dvs. få 
blodproppar i kärlen som omger levern. Detta kan bland annat påverka möjligheten att 
genomgå levertransplantation. Inte bara blodlevringsfaktorerna bildas i levern utan även de 
faktorer som behövs för att hindra blodlevring, så kallade hämmare. Hos friska personer råder 
en balans mellan blodlevringsfaktorer och hämmare. På senare år har forskning indikerat att det 
finns en liknande balans vid leversjukdom, men att den är mycket skörare än hos friska och att 
systemen lättare tippar om barnet t.ex. får en infektion. Det skulle vara värdefullt att finna bra 
analysmetoder som kan ge bra information om balanssituationen för att tidigt kunna ge rätt 
behandling innan en livshotande blödning eller blodpropp bildats. Vi har undersökt en ny typ av 
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analysmetod (trombingenerering) men den kunde tyvärr inte ge mer information än vanliga 
rutinprover.  
 
Studie 3 
Barn med leversjukdom har ofta ett tillstånd som innebär att gallflödet är nedsatt. Detta kallas 
gallstas, eller kolestas, och kan inträffa vid flera olika typer av leversjukdom. Vid gallstas 
ansamlas gallsyror som skadar levercellerna. Vi har studerat om extremt höga nivåer av 
gallsyror kan påverka nivåerna av blodlevringsfaktorer i blodet. Trots att dessa barn kan vara 
mycket sjuka har vi visat att de har oväntat höga nivåer av blodlevringsfaktorer. Vad detta beror 
på är oklart, men det skulle kunna bero på att gallsyror stimulerar levern att öka produktionen 
av blodleveringsfaktorer. Våra fynd kan ha betydelse för bedömning av blodlevringsförmågan 
hos dessa barn men också för bedömning inför en levertransplantation och behöver studeras 
vidare.  
 
Studie 4 
Analyser av blodlevringsfaktorer används för att bedöma barnets prognos och om 
levertransplantation behövs. Internationella studier har dock visat att den vanligaste analysen 
som använts för det, INR, kan visa mycket olika resultat vid olika laboratorier för samma 
patient. I Skandinavien används en annan metod för denna analys och vi har i vår forskning 
kunnat visa att denna ger betydligt mer samstämmiga resultat än de metoder som används i 
USA och stora delar av Europa. Övergång till den Skandinaviska metoden kan således innebära 
en lösning på detta problem. 
 
Slutsats 
I denna avhandling har vi således framgångsrikt behandlat barn med ett nytt läkemedel mot 
blödning och vi har även studerat olika laboratoriemetoder av betydelse för barn med 
leversjukdom. Vi kunde visa att den metod som används i Skandinavien, för ett mycket vanligt 
blodlevringsprov, fungerar bättre för patienter med leversjukdom än de metoder som används 
internationellt. Under arbetets gång har det internationella intresset för blodlevringsrubbningar 
vid leversjukdom ökat vilket innebär stora möjligheter att fortsätta forskningen inom detta 
område i samarbete med andra grupper. Barnen med leversjukdom är förhållandevis få men de 
har ofta svåra sjukdomstillstånd. Att fortsätta arbetet med att förhindra och behandla blödningar 
och blodproppar hos dessa barn liksom att förbättra prognosbedömningen är mycket viktigt, för 
att minska sjukligheten och förbättra överlevnaden.  
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